Absci

Unlocking differentiated biology with generative AI

Founded 2011

Vancouver, United States 158 employees IPO Total: $687.10M AI, Biopharma +2

General Information

Company Name Absci

Founded Year 2011

Location

Vancouver, United States

Founders / Decision Makers

Employees 158

Industries AI, Biopharma, Biotechnology +1

Funding Stage IPO

Business Model B2B, Platform, API

Revenue Model Licensing, Performance Based, Project Based

Hiring 6 roles posted in the month to 7 Nov 2026

Offices as of Nov 2026

Vancouver, United States

Social

BounceWatch is an independent company data service, not affiliated with Absci. To contact Absci, visit absci.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does Absci compare?

A PDF of Absci and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting Absci soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

From the desk

Is Absci on your competitive set?

Our desk can watch it and brief you on every move: hiring, funding, leadership, product and pricing.

Book a 7-day Readout

Discover More

United States Market

Market Signals All Companies

Industry Signals All Companies in United States

Absci Alternatives

All Signals Trend Reports

Recorded by Bounce Watch from public sources. Every entry below carries the date we observed it, and when we have not looked recently the page says so rather than leaving silence to imply nothing happened.

Growth Metrics Oct 28, 2026

Absci's stock soared 12% as part of a rally in AI drug discovery stocks.

In The News Oct 24, 2026

Featured on Yahoo Finance: Is Absci (ABSI) Undervalued As Positive ABS 201 Phase 1 Data Lifts Optimism?

Actively Hiring Oct 23, 2026

Hiring for 6 positions in the last 30 days.

New Partnership Oct 21, 2026

Absci announced a partnership with AMD, deploying a dedicated AMD Instinct™ MI300X cluster for its AI drug discovery platform.

In The News Oct 17, 2026

Featured on Yahoo! Finance Canada: Absci Corporation (ABSI) Stock Price, News, Quote & History

In The News Oct 16, 2026

Featured on Yahoo Finance: Absci (ABSI) Stock Seems Rich Against Its Book Value Backdrop

Absci a competitor of yours? Have our desk watch it

AI Insight

Bounce Watch AI

6 days ago

Absci has recently demonstrated strong strategic momentum, securing a pivotal technology partnership with AMD to enhance its AI drug discovery capabilities and leveraging positive Phase 1 data for its lead therapeutic candidate, ABS-201. The advancement of ABS-201 into a dedicated women's cohort for its Phase 1/2a trial, combined with the AMD collaboration, has fueled a significant rally in its stock, reflecting increased investor optimism in its integrated AI drug creation platform and pipeline progress.

Signal Types

Partnership Clinical Trial Media Attention Stock Performance Product Development

Strategic Labels

Technology Integration Clinical Advancement Market Confidence

Next Move: Product Development

Impact: 9/10

Ideal For: Growth Equity Investors — Publicly Traded Biotech, AI/Pharma Strategic Partners

About Absci

Absci is a forward-thinking company blending AI innovation with biopharmaceutical advancements. Founded in 2011 and headquartered in the United States, the company targets the intersection of AI and biopharma.

With the slogan “Unlocking differentiated biology with generative AI,” Absci emphasizes its unique approach to drug discovery. It employs a data-first AI strategy through its Integrated Drug Creation platform, crafted to design therapeutics and optimize drug leads for challenging biological targets.

Recently, the company secured a $64.00M post-IPO equity investment on 01 September 2025, underscoring investor confidence in its cutting-edge combination of biotechnology and artificial intelligence. This funding positions Absci to further enhance its pioneering drug creation technologies.

For investors, Absci represents a robust opportunity in the rapidly evolving fields of AI and biotechnology, focusing on creating differentiated therapeutics with high market potential.

Business keywords: AI Drug Creation, Generative AI, Biologics Design, De Novo AI Models, AI Lead Optimization, Synthetic Biology, Protein-Based Drugs, Bionic Proteins, Novel Drug Targets, Biotherapeutic Candidates, Integrated Drug Creation Platform, Antibody Development, Deep Learning AI, Pharmaceutical Partnerships, Cell Line Generation

Services & Products

AI Model Development

Biologics Drug Design

Partnered Program Development

Wet Lab Research

Target Customers

Pharmaceutical Companies Biotech Researchers Academic Institutions

Funding Rounds & Investors (13)

View All

Funding Stage	Amount	Investors	Lead Investors	Date
Post-IPO Equity	$100.00M	6	Invus, Redmile Group +4	01 Jun 2026
Post-IPO Equity	$64.00M	-		01 Sep 2025
Post-IPO Equity	$20.00M	1	AMD	01 Jan 2025
Post-IPO Equity	$75.20M	-		01 Feb 2024
IPO	$200.00M	-		01 Jul 2021
Late VC	$125.00M	7	Casdin Capital, D1 Capital Partners +5	01 Mar 2021
Series E	$65.00M	4	Casdin Capital, Redmile Group +2	01 Oct 2020
Debt Financing	$10.40M	5	Columbia Ventures, JSR Life Sciences +3	01 Jan 2020
Series D	$10.40M	2	KBI Biopharma, JSR Corporation	01 Jan 2019
Series C	$12.00M	3	Oregon Entrepreneurship Network, Greenbridge Partners +1	01 May 2018

View All 13 Funding Rounds

Latest News

View All

Absci (ABSI) Stock Could Be Overvalued Given Its Book Value Gap

Yahoo Finance Nov 06, 2026

Absci Soars 12%, Schrödinger Up 11%, Recursion Up 9% as AI Drug Discovery Stocks Rally

Yahoo Finance Oct 28, 2026

Is Absci (ABSI) Undervalued As Positive ABS 201 Phase 1 Data Lifts Optimism?

Yahoo Finance Oct 24, 2026

Absci Accelerates AI Antibody Design on AMD Instinct™ GPUs

AMD Oct 19, 2026

Absci Corporation (ABSI) Stock Price, News, Quote & History

Yahoo! Finance Canada Oct 17, 2026

Absci (ABSI) Stock Seems Rich Against Its Book Value Backdrop

Yahoo Finance Oct 16, 2026

Absci Alternatives & Competitors

View All Alternatives

Absci vs

Profluent United States

Grounded in nature, authored by AI

Venture round

83 employees

AI, Biotechnology

Compare Absci vs Profluent

Absci vs

BioMap United States

Decoding life with AI Foundation Models

102 employees

AI, Life Sciences

Compare Absci vs BioMap

Absci vs

Silica Corpora Germany

In Silica Corpora we design the next generation of Antibody Therapeutics using Generative AI

Grant

3 employees

AI, Biopharma

Also compare with:

AI Proteins

Atomwise View all alternatives

FAQ About Absci

Unlocking differentiated biology with generative AI

Absci was founded in 2011.

Absci is headquartered in Vancouver, United States.

Absci operates in AI, Biopharma, Biotechnology and Life Sciences. Its work centres on AI Drug Creation, Generative AI, Biologics Design and De Novo AI Models. Its customers include Pharmaceutical Companies, Biotech Researchers and Academic Institutions.

Absci has a B2B, Platform and API business model. Its revenue comes from Licensing, Performance Based and Project Based.

Absci has approximately 158 employees.

Absci has completed 13 funding rounds, raising a total of $687.10M. The latest funding stage is IPO.

Absci offers: AI Model Development, Biologics Drug Design, Partnered Program Development, Wet Lab Research.

Top alternatives and competitors to Absci include Profluent, BioMap, Silica Corpora, AI Proteins, Atomwise. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.

Absci and Profluent are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for Absci, https://www.bouncewatch.com/company/absci, updated 8 November 2026. When citing, please name BounceWatch and link this page.

Absci

General Information

Discover More

What changed at Absci recently?

AI Insight

About Absci

Services & Products

Target Customers

Funding Rounds & Investors (13)

Latest News

Absci Alternatives & Competitors

FAQ About Absci